160579-75-9

Upstream product

• 58479-61-1 tert-butylchlorodiphenylsilane 
• 160579-74-8 2(R)-(hydroxymethyl)-1,3-oxathiolane 
• 288-32-4 1H-imidazole 
• 160579-74-8 2-hydroxymethyl-1,3-oxathiolane 

Downstream Products

• 160705-94-2 2R-t-butyldiphenylsilyloxymethyl-4S-(N-4'-acetylcytosin-1'-yl)-1,3-oxathiolane 
• 160579-78-2 2R-t-butyldiphenylsilyloxymethyl-4R-(N-4'-acetylcytosin-1'-yl)-1,3-oxathiolane 
• 160705-96-4 2R-t-butyldiphenylsilyloxymethyl-4S-(N-4'-acetyl-5'-fluorocytosin-1'-yl)-1,3-oxathiolane 
• 160579-79-3 2R-t-butyldiphenylsilyloxymethyl-4R-(N-4'-acetyl-5'-fluorocytosin-1'-yl)-1,3-oxathiolane 
• 160579-80-6 9-[(2R,4R)-2-(tert-Butyl-diphenyl-silanyloxymethyl)-[1,3]oxathiolan-4-yl]-6-chloro-9H-purine 
• 186707-06-2 Trans and Cis-2R-t-butyldiphenylsilyloxymethyl-4-acetoxy-1,3-oxathiolane 
• 160579-76-0 tert-Butyl-((R)-3-oxo-3λ⁴-[1,3]oxathiolan-2-ylmethoxy)-diphenyl-silane 

Relevant academic research and scientific papers

Substituted 1,3-oxathiolanes with antiviral properties

This invention relates to single enantiomers of novel cis-substituted 1,3-oxathiolanes, of the formula (I): wherein; R1is hydrogen, and R2is cytosine or 5-fluorocytosine; and pharmaceutically acceptable salts and esters thereof. This invention also relates to pharmaceutical compositions containing them and to the use of these compounds as antiviral agents, particularly in combination therapy.

Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties

This invention relates to novel substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes or pharmaceutically acceptable salts and esters thereof, of the formula: STR1 wherein X is S, S=O, or SO2 ; Y is O, S, S=O, or SO2 ; R1

Synthesis of Optically Active 2',3'-Dideoxy-3'-oxa-4'-thio-ribonucleoside Analogues by Transposition of a Leaving Group on Chiral Oxathiolanes via a Reductive-oxidative Process

The synthesis of chiral nucleoside analogues with a unique structural feature is reported.The strategy is based on a reductive-oxidative process to complete the transposition of the leaving group in chiral oxathiolanes with known configuration.